AU731106B2 - Method for producing recombinant virus - Google Patents

Method for producing recombinant virus Download PDF

Info

Publication number
AU731106B2
AU731106B2 AU52261/98A AU5226198A AU731106B2 AU 731106 B2 AU731106 B2 AU 731106B2 AU 52261/98 A AU52261/98 A AU 52261/98A AU 5226198 A AU5226198 A AU 5226198A AU 731106 B2 AU731106 B2 AU 731106B2
Authority
AU
Australia
Prior art keywords
baculovirus
genome
region
adenovirus
defective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU52261/98A
Other languages
English (en)
Other versions
AU5226198A (en
Inventor
Helene Leblois-Prehaud
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gencell SAS
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9497899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU731106(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU5226198A publication Critical patent/AU5226198A/en
Application granted granted Critical
Publication of AU731106B2 publication Critical patent/AU731106B2/en
Assigned to GENCELL S.A. reassignment GENCELL S.A. Assignment by Patentee under S 187, Reg 19.1 Assignors: RHONE-POULENC RORER S.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pens And Brushes (AREA)
  • Materials For Medical Uses (AREA)
AU52261/98A 1996-11-22 1997-11-18 Method for producing recombinant virus Expired AU731106B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9614278A FR2756297B1 (fr) 1996-11-22 1996-11-22 Procede de production de virus recombinants
FR96/14278 1996-11-22
PCT/FR1997/002073 WO1998022607A1 (fr) 1996-11-22 1997-11-18 Procede de production de virus recombinants

Publications (2)

Publication Number Publication Date
AU5226198A AU5226198A (en) 1998-06-10
AU731106B2 true AU731106B2 (en) 2001-03-22

Family

ID=9497899

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52261/98A Expired AU731106B2 (en) 1996-11-22 1997-11-18 Method for producing recombinant virus

Country Status (18)

Country Link
US (2) US6387670B1 (enExample)
EP (1) EP0946741B1 (enExample)
JP (1) JP4686670B2 (enExample)
KR (1) KR100719645B1 (enExample)
AT (1) ATE317908T1 (enExample)
AU (1) AU731106B2 (enExample)
BR (1) BR9713388B1 (enExample)
CA (1) CA2271438C (enExample)
CZ (1) CZ293947B6 (enExample)
DE (1) DE69735274T2 (enExample)
ES (1) ES2260803T3 (enExample)
FR (1) FR2756297B1 (enExample)
HU (1) HU224713B1 (enExample)
IL (1) IL129686A (enExample)
NO (2) NO323937B1 (enExample)
SK (1) SK286900B6 (enExample)
WO (1) WO1998022607A1 (enExample)
ZA (1) ZA9710516B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2375119A1 (en) * 1999-05-27 2000-12-07 Genovo, Incorporated Compositions and methods for production of recombinant virus using a carrier vector derived from a nonmammalian virus
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
WO2000073424A1 (en) * 1999-05-28 2000-12-07 Mount Sinai School Of Medicine A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
GB9919409D0 (en) 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
US7897380B2 (en) 2002-08-29 2011-03-01 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
KR101575696B1 (ko) * 2008-03-05 2015-12-08 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 고분자 하이브리드막
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
EP2292781A1 (en) * 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
EP2553105B1 (en) * 2010-04-01 2014-12-17 Weidong Xiao Compositions and methods for the production of recombinant virus vectors
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
US11078464B2 (en) * 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
CN106414474B (zh) 2014-03-17 2021-01-15 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
CA2978068C (en) 2015-03-02 2024-05-28 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
AU2018373279B2 (en) 2017-11-27 2024-07-25 Trames Bio, Inc. Compositions and methods for neurological diseases
BR112020015798A2 (pt) 2018-02-01 2021-03-09 Homology Medicines, Inc. Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
EP3755795A4 (en) 2018-02-19 2022-07-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
BR112020022669A2 (pt) 2018-05-08 2021-02-17 Neuracle Science Co., Ltd distribuição de vírus adenoassociado (aav) de anticorpos anti-fam19a5
JP2022523719A (ja) 2019-01-31 2022-04-26 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ Ａａｖキャプシドの転写依存性定方向進化を使用するための方法
US20220348635A1 (en) 2019-08-21 2022-11-03 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
EP4225382A4 (en) 2020-10-07 2025-04-23 AskBio Inc. ADMINISTRATION OF THERAPEUTIC ADENO-ASSOCIATED VIRUS FUKKUTIN-ASSOCIATED PROTEIN (FKRP) FOR THE TREATMENT OF DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21
EP4514845A1 (en) 2022-04-29 2025-03-05 Broadwing Bio LLC Bispecific antibodies and methods of treating ocular disease
AU2023259251A1 (en) 2022-04-29 2024-11-14 Broadwing Bio Llc Angiopoietin-related protein 7-specific antibodies and uses thereof
CN119365485A (zh) 2022-04-29 2025-01-24 博闻生物有限责任公司 补体因子h相关4特异性抗体及其用途
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
WO2025040613A1 (en) * 2023-08-21 2025-02-27 Vector Biopharma Ag Cell line for production of helper-dependent adenoviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005538A1 (en) * 1988-11-14 1990-05-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Parvovirus capsids
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
EP0785803A4 (en) * 1994-09-23 2000-08-02 Gen Hospital Corp Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell

Also Published As

Publication number Publication date
KR100719645B1 (ko) 2007-05-17
KR20000057202A (ko) 2000-09-15
NO2013009I1 (no) 2013-04-29
HUP0001762A3 (en) 2002-01-28
IL129686A0 (en) 2000-02-29
NO992464D0 (no) 1999-05-21
CA2271438A1 (fr) 1998-05-28
US20030022356A1 (en) 2003-01-30
CA2271438C (fr) 2010-10-26
ZA9710516B (en) 1998-06-10
DE69735274T2 (de) 2006-10-12
NO992464L (no) 1999-06-23
EP0946741A1 (fr) 1999-10-06
ES2260803T3 (es) 2006-11-01
WO1998022607A1 (fr) 1998-05-28
BR9713388B1 (pt) 2009-01-13
CZ293947B6 (cs) 2004-08-18
IL129686A (en) 2005-12-18
FR2756297B1 (fr) 1999-01-08
DE69735274D1 (de) 2006-04-20
ATE317908T1 (de) 2006-03-15
AU5226198A (en) 1998-06-10
SK286900B6 (sk) 2009-07-06
JP4686670B2 (ja) 2011-05-25
HU224713B1 (en) 2006-01-30
FR2756297A1 (fr) 1998-05-29
CZ182299A3 (cs) 1999-08-11
EP0946741B1 (fr) 2006-02-15
SK66699A3 (en) 2000-02-14
HUP0001762A2 (hu) 2000-09-28
JP2001503993A (ja) 2001-03-27
US6387670B1 (en) 2002-05-14
BR9713388A (pt) 2000-03-21
NO323937B1 (no) 2007-07-23

Similar Documents

Publication Publication Date Title
AU731106B2 (en) Method for producing recombinant virus
EP1226264B1 (en) Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
US8236293B2 (en) Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer
US6156497A (en) Recombinase-mediated generation of adenoviral vectors
SK282843B6 (sk) Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
AU2437200A (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
AU726442B2 (en) Generation of replicative molecules in vivo
EP1593742A2 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
MXPA99004449A (en) Method for producing recombinant virus
WO2000073424A1 (en) A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
EP1083229A1 (en) Modified adenoviral vectors for use in gene therapy
AU7560500A (en) Modified adenoviral vectors for use in gene therapy
WO2000072887A1 (en) A novel packaging cell line for the rescue, production and titration of high-capacity adenovirus amplicon vectors
EP1083228A1 (en) Modified adenoviral vectors for use in gene therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GENCELL S.A.

Free format text: FORMER OWNER WAS: RHONE-POULENC RORER S.A.